Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
IRVINE, Calif., March 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a class action lawsuit against Galena Biopharma, Inc. (“Galena” or the “Company”) (Nasdaq:GALE). Investors who purchased or otherwise acquired shares between August 11, 2014 and January 31, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the April 14, 2017 lead plaintiff motion deadline.
If you purchased shares of Galena during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
The complaint alleges that throughout the Class Period, Galena made false and/or misleading statements and/or failed to disclose that: the Company’s sales of Abstral were based on unsustainable sales and marketing practices; that such sales and marketing practices could subject the Company to a criminal investigation; and that as a result of the above, Galena’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On March 10, 2016, the Company disclosed that “[a] federal investigation of two of the high-prescribing physicians for Abstral has resulted in the criminal prosecution of the two physicians for alleged violations of the federal False Claims Act and other federal statutes,” and that the Company was issued a trial subpoena for documents related to that investigation. The Company also noted that “other governmental agencies may be investigating our Abstral promotion practices,” and that “on December 16, 2015, we received a subpoena issued by the U.S. Attorney’s Office in District of New Jersey requesting the production of a broad range of documents pertaining to our marketing and promotional practices for Abstral.”
On January 31, 2017, Galena announced that Mark W. Schwartz, President and Chief Executive Officer during this time, was resigning from his position.
If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contacts Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
